ArticleThoracic cancer2026
Delayed Tumor Shrinkage Beyond Progressive Disease in Small-Cell Lung Cancer Receiving Immunochemotherapy: A Case Report.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small-cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis. Although SCLC initially responds rapidly and drastically to platinum-based chemotherapy, it quickly develops resistance and recurs shortly thereafter. Recently, immunochemotherapy has achieved better survival outcomes than traditional chemotherapy alone, as demonstrated in pivotal trials such as IMpower133 and CASPIAN. However, delayed or atypical tumor responses under immunotherapy remain poorly understood, especially in SCLC. Herein, we present a case of extensive-disease SCLC that showed a delayed tumor shrinkage following transient progression and prolonged elevation of tumor volume and ProGRP levels during immunochemotherapy. This case highlights the potential for delayed response beyond progressive disease even in SCLC, emphasizing the importance of careful evaluation before changing treatment in selected patients receiving immune checkpoint inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.